| __timestamp | Amphastar Pharmaceuticals, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 7751000 |
| Thursday, January 1, 2015 | 46974000 | 10251000 |
| Friday, January 1, 2016 | 47298000 | 9575000 |
| Sunday, January 1, 2017 | 50918000 | 10912000 |
| Monday, January 1, 2018 | 58044000 | 11049000 |
| Tuesday, January 1, 2019 | 63109000 | 11646000 |
| Wednesday, January 1, 2020 | 65157000 | 13265000 |
| Friday, January 1, 2021 | 68920000 | 25805000 |
| Saturday, January 1, 2022 | 66592000 | 35182000 |
| Sunday, January 1, 2023 | 80393000 | 94999000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Amphastar's SG&A expenses have steadily increased by approximately 99% from 2014 to 2023, reflecting a strategic expansion and investment in operational capabilities. In contrast, Viridian's SG&A expenses surged dramatically, especially in recent years, with a staggering increase of over 1,100% from 2014 to 2023. This sharp rise suggests aggressive scaling and possibly a shift in business strategy. The year 2023 marked a pivotal point where Viridian's SG&A expenses surpassed Amphastar's, indicating a potential shift in market dynamics. These trends offer a window into the strategic priorities and growth trajectories of these two pharmaceutical players.
Who Optimizes SG&A Costs Better? Sanofi or Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Viridian Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.